NBIX Fair Value Estimate
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Neurocrine Biosciences Inc
Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science.
Earnings per share grew at a 50.0% CAGR.
Current Price
$131.78
+0.08%GoodMoat Value
$213.39
61.9% undervaluedBlended fair value estimate based on DCF, Graham Number, and earnings-based models.
Graham Number, PEG-based, and Earnings-based models
View Fair Value →Neurocrine Biosciences Inc (NBIX) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Neurocrine Biosciences Inc is $213.39. The current stock price is $131.78, suggesting the stock is 61.9% undervalued.
The price-to-earnings (P/E) ratio is 27.45. Price-to-book ratio is 4.04. Price-to-sales ratio is 4.59. Enterprise value to EBITDA is 15.84. PEG ratio is 0.55.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Neurocrine Biosciences Inc's intrinsic value.